K
K. Mattson
Researcher at University of Texas MD Anderson Cancer Center
Publications - 7
Citations - 953
K. Mattson is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Vinorelbine & Carboplatin. The author has an hindex of 4, co-authored 7 publications receiving 931 citations.
Papers
More filters
Journal ArticleDOI
Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group
Frank V. Fossella,José Rodrigues Pereira,Joachim von Pawel,Anna Pluzanska,Vera Gorbounova,E. Kaukel,K. Mattson,Rodryg Ramlau,Aleksandra Szczesna,Panagiotis Fidias,Michael Millward,Chandra P. Belani +11 more
TL;DR: DC resulted in a more favorable overall response and survival rate than VC, demonstrating that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.
Journal ArticleDOI
P-452 Phase III study of docetaxel-cisplatin (DC) or docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) as first-line treatment of advanced non-small cell lung cancer (NSCLC): Analyses by gender
Chandra P. Belani,J. von Pawel,Anna Pluzanska,Vera Gorbounova,E. Kaukel,K. Mattson,Rodryg Ramlau,Panagiotis Fidias,Michael Millward,Frank V. Fossella +9 more
Journal ArticleDOI
Vinorelbine (NVB)-carboplatin (CBDCA) vs non-platinum doublets in inoperable non-small cell lung cancer (NSCLC) patients (pts)-final results of the Glob 2 phase III with patient benefit analysis
Raymond P. Abratt,Aleksandra Szczesna,K. Mattson,M. Wernli,P. Reiterer,Rina Hui,J. Lizon,Oscar Bertetto,Martin Reck,Eng Huat Tan +9 more
TL;DR: NVB-GEM given as a non-P doublet in this phase III has demonstrated OR, PFS and clinical benefit comparable to NVB-CBDCA doublet with a favorable MS and tolerance profile.
Journal ArticleDOI
MTA (LY231514): a phase II trial in patients (PTS) with non-small cell lung cancer (NSCLC) who relapsed after previous platinum or non-platinum chemotherapy
J. von Pawel,Christian Manegold,K. Mattson,Pe Postmus,Egbert F. Smit,Stephen Clarke,A. Saarinen +6 more
Journal ArticleDOI
Erratum: GLOB-1: A prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients (Annals of Oncology) (2002) vol. 13 (1853-1861))
Pierre-Jean Souquet,Allan Price,M. Jaworski,J.-P. Burillon,D. Aubert,O. Fernández,Ceri Lewis,P. de Souza,L Bosque,J. Rodrigues Pereira,V Kolec,M Marel,P Astoul,A Jounieaux,R Riou,V Tack,K.M. Deppermann,U Gatzmeier,G. Koschel,E D Kreuser,G Schlimok,J. von Pawel,O P Isokangas,K. Mattson,L Torrecillas,V Lira Puerto,N Barroso,R. Van Klaveren,D Gallardo,B Utraka,P Barnardt,Eng Huat Tan,I. Sevilla García,J A Moreno Nogueira,Daniel C. Betticher,Rolf A. Stahel,M. Wernli,J F Shih,P I Clark,Peter Harper +39 more